Antimuscarinics Pediatric Studies May Be Required By FDA For Off-Label Use
Executive Summary
FDA is considering requiring pediatric studies of antimuscarinics as an option for obtaining information on products used to treat excessive drooling in children, an off-label indication.
You may also be interested in...
Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
Congress should consider allowing pediatric exclusivity periods to be licensed to other sponsors as a mechanism for promoting pediatric study of drug products that do not have patent protection or exclusivity, FDA's pediatric exclusivity status report suggests.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials